Safety of nivolumab in combination with dendritic cell vaccines in recurrent high-grade glioma.

Katherine B. Peters,Gerald E. Archer,Pamela K. Norberg,Weihua Xie,Stevie Threatt,Eric S. Lipp,James E. Herndon,Patrick Healy,Kendra L. Congdon,Luis Sanchez-Perez,Henry S. Friedman,Annick Desjardins,Gordana Vlahovic,John H. Sampson

Safety of nivolumab in combination with dendritic cell vaccines in recurrent high-grade glioma.

2019

Katherine B. Peters
Gerald E. Archer
Pamela K. Norberg
Weihua Xie
Stevie Threatt
Eric S. Lipp
James E. Herndon
Patrick Healy
Kendra L. Congdon
Luis Sanchez-Perez
Henry S. Friedman
Annick Desjardins
Gordana Vlahovic
John H. Sampson

e13526Background: Recurrence of high-grade glioma (HGG) (WHO grade III-IV) is a nearly universal phenomenon and necessitates the development of new therapeutic modalities. Two possible immunotherap...

Keywords:

Cancer research
Nivolumab
Pathology
Dendritic cell
High-Grade Glioma
Medicine
Glioma
therapeutic modalities
who grade
Oncology
Internal medicine

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations